GlassScriptPhysician profile
Jonathan Thomas Lale
NPI 1336724632
$1,970.15
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $251 · 2022: $529 · 2023: $786 · 2024: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,190.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $356.06 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $351.30 | 2021-2024 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $335.49 | 2022-2024 | |
| Pfizer INC. | $155.56 | 2021-2024 | |
| Lilly USA, LLC | $75.67 | 2022-2024 | Mounjaro, Zepbound |
| Hologic Sales and Service, LLC | $63.29 | 2022-2024 | Thinprep 2000 Processor, Aptima |
| Horizon Therapeutics Plc | $56.50 | 2021-2023 | Krystexxa |
| Myriad Women'S Health, INC. | $49.96 | 2023 | Myrisk |
| Amgen INC. | $49.83 | 2022-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $47.78 | 2023-2024 | Spravato, Xarelto |
| Boston Scientific Corporation | $47.20 | 2023-2024 | Wavewriter Alpha Prime 16 |
| Biohaven Pharmaceutical Holding Company LTD. | $45.17 | 2022 | |
| Idorsia Pharmaceuticals US INC | $38.84 | 2022-2023 | Quviviq |
| Exact Sciences Corporation | $34.74 | 2023 | Cologuard Collection Kit |
| Ultragenyx Pharmaceutical INC. | $34.62 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $30.81 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $22.09 | 2022 | |
| Alexion Pharmaceuticals, INC. | $20.79 | 2023 | Strensiq |
| Genentech USA, INC. | $20.79 | 2021 | |
| Optinose US, INC. | $20.03 | 2022 | |
| Dexcom, INC. | $18.82 | 2023 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $18.57 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.86 | 2021 | |
| Paratek Pharmaceuticals, INC. | $17.58 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.87 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.23 | 2022 | |
| Eisai INC. | $11.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Lale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.